Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 4Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 21Prostatic Neoplasms 17Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Recurrence 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4regorafenib 3Specimen Handling 3Nivolumab 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2pembrolizumab 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2cabozantinib 2Etoposide 2Docetaxel 2tocilizumab 1tazemetostat 1poly ICLC 1palbociclib 1naxitamab 1mifamurtide 1humanized 3F8 anti-GD2 monoclonal antibody 1glucarpidase 1gamma-Glutamyl Hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Osteosarcoma × Docetaxel × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

NCT06935409 2026-04-09

Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

Hansoh BioMedical R&D Company

Phase 3 Active not recruiting
117 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡